BE2017C059I2 - - Google Patents

Download PDF

Info

Publication number: BE2017C059I2
Authority: BE; Belgium

Application number

BE2017C059C

Other languages

Dutch (nl)

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-10

Filing date

2017-11-28

Publication date

2021-11-22

2017-11-28 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2021-11-22 Publication of BE2017C059I2 publication Critical patent/BE2017C059I2/nl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2445—Beta-glucosidase (3.2.1.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01021—Beta-glucosidase (3.2.1.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Virology (AREA)
Hematology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Analytical Chemistry (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)

BE2017C059C 2001-10-10 2017-11-28 BE2017C059I2 (da)

Applications Claiming Priority (10)

Application Number	Priority Date	Filing Date	Title
US32852301P	2001-10-10	2001-10-10
US34469201P	2001-10-19	2001-10-19
US33430101P	2001-11-28	2001-11-28
US33423301P	2001-11-28	2001-11-28
US38729202P	2002-06-07	2002-06-07
US39177702P	2002-06-25	2002-06-25
US39659402P	2002-07-17	2002-07-17
US40424902P	2002-08-16	2002-08-16
US40752702P	2002-08-28	2002-08-28
EP02795509A EP1578771B1 (en)	2001-10-10	2002-10-09	Remodeling and glycoconjugation of peptides

Publications (1)

Publication Number	Publication Date
BE2017C059I2 true BE2017C059I2 (da)	2021-11-22

Family

ID=27578810

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BE2014C004C BE2014C004I2 (da)	2001-10-10	2014-01-24
BE2017C059C BE2017C059I2 (da)	2001-10-10	2017-11-28

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BE2014C004C BE2014C004I2 (da)	2001-10-10	2014-01-24

Country Status (21)

Country	Link
US (3)	US7416858B2 (da)
EP (14)	EP1578771B1 (da)
JP (8)	JP5232352B2 (da)
CN (4)	CN105131104B (da)
AU (2)	AU2002360264B2 (da)
BE (2)	BE2014C004I2 (da)
BR (1)	BRPI0213207B1 (da)
CA (1)	CA2462930C (da)
DK (4)	DK2279755T3 (da)
ES (9)	ES2466024T3 (da)
FR (2)	FR14C0007I2 (da)
HK (1)	HK1080090B (da)
IL (3)	IL161251A0 (da)
LU (1)	LU92359I2 (da)
MX (1)	MXPA04003333A (da)
NL (1)	NL300912I2 (da)
NZ (1)	NZ532027A (da)
PT (2)	PT2279753E (da)
SG (2)	SG177002A1 (da)
WO (1)	WO2003031464A2 (da)
ZA (2)	ZA200700168B (da)

Families Citing this family (332)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5581476A (en) *	1993-01-28	1996-12-03	Amgen Inc.	Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5545553A (en) *	1994-09-26	1996-08-13	The Rockefeller University	Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
WO2001045746A2 (en)	1999-12-24	2001-06-28	Genentech, Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1803730A1 (en)	2000-04-12	2007-07-04	Human Genome Sciences, Inc.	Albumin fusion proteins
US7863020B2 (en)	2000-06-28	2011-01-04	Glycofi, Inc.	Production of sialylated N-glycans in lower eukaryotes
US7449308B2 (en)	2000-06-28	2008-11-11	Glycofi, Inc.	Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7625756B2 (en) *	2000-06-28	2009-12-01	GycoFi, Inc.	Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7598055B2 (en)	2000-06-28	2009-10-06	Glycofi, Inc.	N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7723296B2 (en)	2001-01-18	2010-05-25	Genzyme Corporation	Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7507413B2 (en) *	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US7112410B1 (en)	2001-08-29	2006-09-26	Human Genome Sciences, Inc.	Human tumor necrosis factor TR21 and methods based thereon
US7214660B2 (en)	2001-10-10	2007-05-08	Neose Technologies, Inc.	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7179617B2 (en) *	2001-10-10	2007-02-20	Neose Technologies, Inc.	Factor IX: remolding and glycoconjugation of Factor IX
US7696163B2 (en)	2001-10-10	2010-04-13	Novo Nordisk A/S	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en)	2001-10-10	2007-02-06	Neose Technologies, Inc.	Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
CN105131104B (zh) *	2001-10-10	2018-11-16	诺和诺德公司	肽的重构和糖缀合
US7399613B2 (en) *	2001-10-10	2008-07-15	Neose Technologies, Inc.	Sialic acid nucleotide sugars
US7439043B2 (en) *	2001-10-10	2008-10-21	Neose Technologies, Inc.	Galactosyl nucleotide sugars
US7795210B2 (en)	2001-10-10	2010-09-14	Novo Nordisk A/S	Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en)	2001-10-10	2011-08-30	Novo Nordisk A/S	Factor VII: remodeling and glycoconjugation of Factor VII
US7157277B2 (en)	2001-11-28	2007-01-02	Neose Technologies, Inc.	Factor VIII remodeling and glycoconjugation of Factor VIII
CA2465007C (en)	2001-10-29	2012-01-17	Crucell Holland B.V.	Methods and means for producing proteins with predetermined post-translational modifications
US7473680B2 (en) *	2001-11-28	2009-01-06	Neose Technologies, Inc.	Remodeling and glycoconjugation of peptides
EP1997829A1 (en) *	2001-12-21	2008-12-03	Human Genome Sciences, Inc.	Albumin fusion proteins
JP2006506317A (ja)	2002-01-11	2006-02-23	バイオマリンファーマシューティカルインコーポレイテッド	治療用リソソーム酵素の送達のための酵素送達系としてのｐ９７の使用
DE10209821A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung von Proteinen an ein modifiziertes Polysaccharid
MXPA04012496A (es)	2002-06-21	2005-09-12	Novo Nordisk Healthcare Ag	Glicoformos del factor vii pegilados.
CN1671722A (zh) *	2002-08-01	2005-09-21	加拿大国家研究院	弯曲菌的聚糖和糖肽
EP1534324B1 (en)	2002-08-20	2019-01-16	Glykos Finland Oy	Tumor specific oligosaccharide epitopes and use thereof
CA2498319A1 (en) *	2002-09-09	2004-03-18	Nautilus Biotech	Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
DE60323756D1 (de)	2002-10-08	2008-11-06	Fresenius Kabi De Gmbh	Pharmazeutisch aktive oligosaccharid-conjugate
ES2333422T3 (es)	2002-10-16	2010-02-22	The Scripps Research Institute	Sintesis de glicoproteinas.
EP1562422A4 (en) *	2002-11-08	2012-04-25	Brigham & Womens Hospital	COMPOSITIONS AND METHODS FOR EXTENDING THE SURVIVAL OF BLOODPLATES
US7332299B2 (en)	2003-02-20	2008-02-19	Glycofi, Inc.	Endomannosidases in the modification of glycoproteins in eukaryotes
AU2004221824B2 (en) *	2003-03-14	2009-08-27	Ratiopharm Gmbh	Branched water-soluble polymers and their conjugates
WO2004091487A2 (en) *	2003-04-09	2004-10-28	Wyeth	Hemophilia treatment by inhalation of coagulation factors
US8791070B2 (en)	2003-04-09	2014-07-29	Novo Nordisk A/S	Glycopegylated factor IX
SG155777A1 (en)	2003-04-09	2009-10-29	Neose Technologies Inc	Glycopegylation methods and proteins/peptides produced by the methods
WO2004091499A2 (en) *	2003-04-09	2004-10-28	Neose Technologies, Inc.	Intracellular formation of peptide conjugates
JP2007523630A (ja) *	2003-05-09	2007-08-23	ネオステクノロジーズインコーポレイテッド	ヒト成長ホルモングリコシル化突然変異体の組成と調合法
US9005625B2 (en)	2003-07-25	2015-04-14	Novo Nordisk A/S	Antibody toxin conjugates
WO2005014655A2 (en)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
EP2198876B1 (en) *	2003-10-24	2012-12-05	Nora Therapeutics, Inc.	A method for reducing the likelihood of implantation failure in a subject
US8338373B2 (en) *	2003-10-24	2012-12-25	Nora Therapeutics, Inc.	Method for reducing the risk of spontaneous abortion in a human female subject
US20090226397A1 (en) *	2003-10-24	2009-09-10	Nora Therapeutics, Inc.	Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US7507573B2 (en)	2003-11-14	2009-03-24	Vib, Vzw	Modification of protein glycosylation in methylotrophic yeast
US20070258986A1 (en) *	2003-11-19	2007-11-08	Govt of the US as represented by the secretary,	Targeted Delivery System for Bioactive Agents
US8633157B2 (en)	2003-11-24	2014-01-21	Novo Nordisk A/S	Glycopegylated erythropoietin
US20080305992A1 (en) *	2003-11-24	2008-12-11	Neose Technologies, Inc.	Glycopegylated erythropoietin
US20070254834A1 (en) *	2003-11-24	2007-11-01	Defrees Shawn	Glycopegylated Erythropoietin
ES2507091T3 (es)	2003-12-01	2014-10-14	Novo Nordisk Health Care Ag	Nanofiltración de soluciones del factor VII para eliminar virus
US20060040856A1 (en)	2003-12-03	2006-02-23	Neose Technologies, Inc.	Glycopegylated factor IX
MXPA06006029A (es) *	2003-12-03	2006-08-23	Neose Technologies Inc	Factor de estimulacion de colonias de granulocitos modificado por glicopolietilenglicol.
US7956032B2 (en) *	2003-12-03	2011-06-07	Novo Nordisk A/S	Glycopegylated granulocyte colony stimulating factor
CA2549413A1 (en) *	2003-12-03	2005-06-23	Neose Technologies, Inc.	Glycopegylated factor ix
US20080318850A1 (en) *	2003-12-03	2008-12-25	Neose Technologies, Inc.	Glycopegylated Factor Ix
KR20140093711A (ko)	2003-12-19	2014-07-28	노보 노르디스크 헬스 케어 악티엔게젤샤프트	인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
ES2560657T3 (es)	2004-01-08	2016-02-22	Ratiopharm Gmbh	Glicosilación con unión en O de péptidos G-CSF
EP1720892B1 (en) *	2004-01-26	2013-07-24	BioGeneriX AG	Branched polymer-modified sugars and nucleotides
ES2433867T3 (es) *	2004-01-26	2013-12-12	Biogenerix Ag	Azúcares y nucleótidos modificados con polímeros ramificados
NZ548256A (en) *	2004-02-02	2010-02-26	Ambrx Inc	Modified human four helical bundle polypeptides and their uses
HUE027902T2 (en) *	2004-02-09	2016-11-28	Human Genome Sciences Inc Corp Service Company	Albumin fusion proteins
AR048098A1 (es) *	2004-03-15	2006-03-29	Wyeth Corp	Conjugados de caliqueamicina
JP2007530569A (ja) *	2004-03-23	2007-11-01	アムジエン・インコーポレーテツド	化学修飾タンパク質組成物及び方法
KR20070008645A (ko)	2004-05-04	2007-01-17	노보 노르디스크 헬스 케어 악티엔게젤샤프트	폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법
US20050287639A1 (en)	2004-05-17	2005-12-29	California Institute Of Technology	Methods of incorporating amino acid analogs into proteins
AU2014280936B2 (en) *	2004-06-30	2016-12-15	Nektar Therapeutics	Polymer-factor ix moiety conjugates
KR101100059B1 (ko) *	2004-06-30	2011-12-29	넥타르 테라퓨틱스	중합체인자 ｉｘ 부분의 접합체
WO2006010143A2 (en)	2004-07-13	2006-01-26	Neose Technologies, Inc.	Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US20090292110A1 (en) *	2004-07-23	2009-11-26	Defrees Shawn	Enzymatic modification of glycopeptides
CA2621250A1 (en)	2004-09-07	2006-03-16	Zymequest, Inc.	Apparatus for prolonging survival of platelets
EP1799249A2 (en)	2004-09-10	2007-06-27	Neose Technologies, Inc.	Glycopegylated interferon alpha
AU2005294723A1 (en) *	2004-10-05	2006-04-20	Genentech, Inc.	Therapeutic agents with decreased toxicity
CA2626363A1 (en) *	2004-10-15	2006-04-27	Zymequest, Inc.	Compositions and methods for prolonging survival of platelets
US7378263B2 (en)	2004-10-20	2008-05-27	The Scripps Research Institute	In vivo site-specific incorporation of N-acetyl-galactosamine amino acids in eubacteria
PL2586456T3 (pl)	2004-10-29	2016-07-29	Ratiopharm Gmbh	Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF)
US20090054623A1 (en) *	2004-12-17	2009-02-26	Neose Technologies, Inc.	Lipo-Conjugation of Peptides
AU2005318106B2 (en)	2004-12-23	2011-11-03	Novo Nordisk Health Care Ag	Reduction of the content of protein contaminants in compositions comprising a Vitamin K-dependent protein of interest
JP2008526864A (ja) *	2005-01-06	2008-07-24	ネオステクノロジーズインコーポレイテッド	糖断片を用いる糖結合
US9029331B2 (en)	2005-01-10	2015-05-12	Novo Nordisk A/S	Glycopegylated granulocyte colony stimulating factor
CA2595676A1 (en) *	2005-01-25	2006-08-03	Apollo Life Sciences Limited	Molecules and chimeric molecules thereof
JP2008529505A (ja) *	2005-02-15	2008-08-07	アポロライフサイエンシズリミテッド	分子およびそのキメラ分子
EP1861124A2 (en) *	2005-03-11	2007-12-05	Fresenius Kabi Deutschland GmbH	Production of bioactive glycoproteins from inactive starting materials by conjugation with hydroxyalkylstarch
WO2006102652A2 (en) *	2005-03-24	2006-09-28	Neose Technologies, Inc.	Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
JP2008538181A (ja) *	2005-03-30	2008-10-16	ネオステクノロジーズインコーポレイテッド	昆虫細胞系において増殖させたペプチドを生産するための製造方法
DE602006017351D1 (de) *	2005-03-31	2010-11-18	Inst Noguchi	Analyseverfahren für biologische probe und screening-verfahren für krankheitsmarker
EP1871795A4 (en) *	2005-04-08	2010-03-31	Biogenerix Ag	COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
US20060246523A1 (en)	2005-04-28	2006-11-02	Christopher Bieniarz	Antibody conjugates
WO2006127910A2 (en)	2005-05-25	2006-11-30	Neose Technologies, Inc.	Glycopegylated erythropoietin formulations
US20110003744A1 (en) *	2005-05-25	2011-01-06	Novo Nordisk A/S	Glycopegylated Erythropoietin Formulations
EP1891231A4 (en) *	2005-05-25	2011-06-22	Novo Nordisk As	GLYCOPEGYLATED FACTOR IX
WO2006134173A2 (en)	2005-06-17	2006-12-21	Novo Nordisk Health Care Ag	Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
WO2007006808A1 (en)	2005-07-13	2007-01-18	Novo Nordisk Health Care Ag	Host cell protein knock-out cells for production of therapeutic proteins
US20070105755A1 (en)	2005-10-26	2007-05-10	Neose Technologies, Inc.	One pot desialylation and glycopegylation of therapeutic peptides
BRPI0614839A2 (pt) *	2005-08-19	2009-05-19	Neose Technologies Inc	fator vii e fator viia glicopeguilados
CA2619825A1 (en) *	2005-08-19	2007-03-01	Centocor, Inc.	Proteolysis resistant antibody preparations
WO2007026021A1 (en)	2005-09-01	2007-03-08	Novo Nordisk Health Care Ag	Hydrophobic interaction chromatography purification of factor vii polypeptides
EP2316930A1 (en)	2005-09-14	2011-05-04	Novo Nordisk Health Care AG	Human coagulation factor VII polypeptides
EP1954304A4 (en) *	2005-10-14	2010-03-10	Zymequest Inc	COMPOSITIONS AND METHOD FOR EXTENDING THE LIFE OF PLATES
JP2009514814A (ja) *	2005-10-21	2009-04-09	シナジェバ・バイオファーマ・コーポレイション	グリコール化およびグリコシル化された家禽類由来の治療用たんぱく質
WO2007056191A2 (en)	2005-11-03	2007-05-18	Neose Technologies, Inc.	Nucleotide sugar purification using membranes
US8247530B2 (en) *	2005-11-08	2012-08-21	Palatin Technologies, Inc.	N-alkylated cyclic peptide melanocortin agonists
US20070117153A1 (en)	2005-11-23	2007-05-24	Christopher Bieniarz	Molecular conjugate
EP1816201A1 (en) *	2006-02-06	2007-08-08	CSL Behring GmbH	Modified coagulation factor VIIa with extended half-life
EP1987068B1 (en) †	2006-02-10	2018-08-08	Life Technologies Corporation	Oligosaccharide modification and labeling of proteins
CA2647632C (en)	2006-03-27	2017-06-27	University Of Maryland Biotechnology Institute	Glycoprotein synthesis and remodeling by enzymatic transglycosylation
NZ572050A (en) *	2006-03-31	2011-09-30	Baxter Int	Factor VIII conjugated to polyethylene glycol
US7985839B2 (en) *	2006-03-31	2011-07-26	Baxter International Inc.	Factor VIII polymer conjugates
US7982010B2 (en) *	2006-03-31	2011-07-19	Baxter International Inc.	Factor VIII polymer conjugates
US7645860B2 (en) *	2006-03-31	2010-01-12	Baxter Healthcare S.A.	Factor VIII polymer conjugates
WO2007117685A2 (en)	2006-04-07	2007-10-18	Nektar Therapeutics Al, Corporation	Conjugates of an anti-tnf-alpha antibody
EP2013357A4 (en)	2006-04-19	2012-02-22	Biogenerix Ag	EXPRESSION OF O-GLYCOSYLATED THERAPEUTIC PROTEINS IN PROKARYOTIC MICROORGANISMS
EP2444499A3 (en)	2006-05-02	2012-05-09	Allozyne, Inc.	Amino acid substituted molecules
EP2474318A1 (en) *	2006-06-07	2012-07-11	Human Genome Sciences, Inc.	Albumin fusion proteins
US20100173323A1 (en) *	2006-06-09	2010-07-08	University Of Maryland, Baltimore	Glycosylation engineered antibody therapy
AR078117A1 (es)	2006-06-20	2011-10-19	Protech Pharma S A	Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
US20080248959A1 (en) *	2006-07-21	2008-10-09	Neose Technologies, Inc.	Glycosylation of peptides via o-linked glycosylation sequences
CN101511391B (zh)	2006-07-25	2013-03-13	利普生技术有限公司	N末端聚唾液酸化
JP2010505874A (ja) *	2006-10-03	2010-02-25	ノヴォノルディスクアー／エス	ポリペプチドコンジュゲートの精製方法
MX2009003470A (es) *	2006-10-04	2009-04-14	Novo Nordisk As	Azucares y glicopeptidos pegilados enlazados a glicerol.
US20080207487A1 (en) *	2006-11-02	2008-08-28	Neose Technologies, Inc.	Manufacturing process for the production of polypeptides expressed in insect cell-lines
KR101248252B1 (ko)	2006-11-28	2013-03-27	한올바이오파마주식회사	변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
CN103804489A (zh)	2006-12-15	2014-05-21	巴克斯特国际公司	具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
DK2121713T3 (da)	2007-01-18	2013-06-24	Genzyme Corp	Oligosaccharider, omfattende en aminooxygruppe, og konjugater deraf
WO2008089339A2 (en) *	2007-01-18	2008-07-24	Genzyme Corporation	Oligosaccharide conjugates for cellular targeting
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
HRP20120522T1 (hr) *	2007-03-30	2012-08-31	Ambrx	Modificirani fgf-21 polipeptidi i njihova uporaba
BRPI0809670A8 (pt)	2007-04-03	2018-12-18	Biogenerix Ag	métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral.
US9395352B2 (en)	2007-04-06	2016-07-19	Arizona Board Of Regents On Behalf Of Arizona State University	Devices and methods for target molecule characterization
US20090053167A1 (en) *	2007-05-14	2009-02-26	Neose Technologies, Inc.	C-, S- and N-glycosylation of peptides
MX2009013259A (es) *	2007-06-12	2010-01-25	Novo Nordisk As	Proceso mejorado para la produccion de azucares de nucleotidos.
US20100268055A1 (en) *	2007-07-19	2010-10-21	Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University	Self-Anchoring MEMS Intrafascicular Neural Electrode
US8933197B2 (en) *	2007-08-15	2015-01-13	Amunix Operating Inc.	Compositions comprising modified biologically active polypeptides
NZ583276A (en)	2007-08-27	2012-06-29	Biogenerix Ag	Liquid formulations of granulocyte colony stimulating factor and polymer conjugates
US8207112B2 (en)	2007-08-29	2012-06-26	Biogenerix Ag	Liquid formulation of G-CSF conjugate
BRPI0820271A2 (pt) *	2007-11-09	2015-05-26	Baxter Int	Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada.
CN105052834A (zh) *	2008-01-07	2015-11-18	亚莱克逊药物有限公司	禽类的糖基化
WO2009089396A2 (en) *	2008-01-08	2009-07-16	Neose Technologies, Inc.	Glycoconjugation of polypeptides using oligosaccharyltransferases
ES2476690T3 (es)	2008-02-27	2014-07-15	Novo Nordisk A/S	Moléculas conjugadas del Factor VIII
WO2009117522A2 (en)	2008-03-18	2009-09-24	Reinhart, Kevin	Nanopore and carbon nanotube based dna sequencer and a serial recognition sequencer
WO2009117517A2 (en)	2008-03-18	2009-09-24	Arizona Board Of Regents Acting For And On Behalf Of Arizona State University	Nanopore and carbon nanotube based dna sequencer
CA2728708A1 (en) *	2008-06-25	2009-12-30	Bayer Healthcare Llc	Factor viii muteins with reduced immunogenicity
DK2318832T3 (da)	2008-07-15	2014-01-20	Academia Sinica	Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
WO2010042514A1 (en)	2008-10-06	2010-04-15	Arizona Board Of Regents	Nanopore and carbon nanotube based dna sequencer and a serial recognition elements
HUE044381T2 (hu)	2008-12-16	2019-10-28	Genzyme Corp	Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához
CA2750262C (en)	2009-01-28	2016-08-09	Smartcells, Inc.	Conjugate based systems for controlled drug delivery
BR122021021381B1 (pt)	2009-02-03	2023-05-16	Amunix Pharmaceuticals, Inc	Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
WO2010096394A2 (en)	2009-02-17	2010-08-26	Redwood Biosciences, Inc.	Aldehyde-tagged protein-based drug carriers and methods of use
WO2010111530A1 (en)	2009-03-25	2010-09-30	Seneb Biosciences, Inc.	Glycolipids as treatment for disease
WO2010115866A1 (en)	2009-04-06	2010-10-14	Novo Nordisk A/S	Targeted delivery of factor viii proteins to platelets
CA2768155C (en) *	2009-06-16	2016-08-23	The University Of Bath	Materials and methods relating to glycosylation
US8642737B2 (en)	2010-07-26	2014-02-04	Baxter International Inc.	Nucleophilic catalysts for oxime linkage
US8809501B2 (en)	2009-07-27	2014-08-19	Baxter International Inc.	Nucleophilic catalysts for oxime linkage
KR101912335B1 (ko)	2009-07-27	2018-10-26	리폭센 테크놀로지즈 리미티드	비혈액 응고 단백질의 글리코폴리시알화
KR101759300B1 (ko) *	2009-07-27	2017-07-31	리폭센 테크놀로지즈 리미티드	비혈액 응고 단백질의 글리코폴리시알화
SG10201401194VA (en)	2009-07-27	2014-07-30	Lipoxen Technologies Ltd	Glycopolysialylation of non-blood coagulation proteins
WO2011018515A1 (en)	2009-08-14	2011-02-17	Novo Nordisk Health Care Ag	Method of purifying pegylated proteins
JP2013502458A (ja)	2009-08-24	2013-01-24	アムニクスオペレーティングインコーポレイテッド	凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
GB0915403D0 (en) *	2009-09-04	2009-10-07	London School Hygiene & Tropical Medicine	Protein glycosylation
AU2010308030B2 (en)	2009-10-12	2014-05-29	Pfizer Inc.	Cancer treatment
WO2011064247A1 (en)	2009-11-24	2011-06-03	Novo Nordisk Health Care Ag	Method of purifying pegylated proteins
US10087236B2 (en) *	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
EP2507267B1 (en) *	2009-12-02	2016-09-14	Acceleron Pharma, Inc.	Compositions and methods for increasing serum half-life of fc fusion proteins
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US9493543B2 (en)	2010-02-16	2016-11-15	Novo Nordisk A/S	Factor VIII fusion protein
EP2536753B1 (en)	2010-02-16	2017-12-20	Novo Nordisk A/S	Factor viii molecules with reduced vwf binding
NZ602255A (en)	2010-03-04	2014-04-30	Pfenex Inc	Method for producing soluble recombinant interferon protein without denaturing
CA2794740C (en)	2010-04-01	2019-12-31	Pfenex Inc.	Methods for g-csf production in a pseudomonas host cell
WO2011130332A1 (en)	2010-04-12	2011-10-20	Academia Sinica	Glycan arrays for high throughput screening of viruses
US8962345B2 (en) *	2010-05-21	2015-02-24	The United States Of America As Represented By The Secretary Of Commerce	Method of characterizing glycans attached to glycoproteins
CN103080135B (zh)	2010-06-30	2017-06-13	诺沃—诺迪斯克有限公司	能够特异性结合组织因子途径抑制剂的抗体
KR20230156435A (ko)	2010-07-09	2023-11-14	바이오버라티브 테라퓨틱스 인크.	인자 iｘ 폴리펩티드 및 이들의 사용 방법
WO2012007324A2 (en)	2010-07-15	2012-01-19	Novo Nordisk A/S	Stabilized factor viii variants
CA2806399A1 (en)	2010-07-28	2012-02-02	Smartcells, Inc.	Recombinantly expressed insulin polypeptides and uses thereof
JP2013535198A (ja)	2010-07-30	2013-09-12	グリコド	哺乳類のグリコシル化経路を有する酵母人工染色体
PT2415779E (pt)	2010-08-02	2015-05-13	Ratiopharm Gmbh	Processo de produção e purificação de uma sialiltransferase solúvel activa
EP2640745B1 (en)	2010-09-10	2018-11-07	MedImmune Limited	Bivalent and bispecific anti-il6/anti-il23 antibodies
JP6042335B2 (ja)	2010-09-15	2016-12-14	ノヴォノルディスクアー／エス	細胞取込みが低下した第ｖｉｉｉ因子変異体
EP2619228A1 (en)	2010-09-22	2013-07-31	Novo Nordisk A/S	Therapeutic factor viii antibodies
CA2815266C (en)	2010-11-05	2023-09-05	Zymeworks Inc.	Stable heterodimeric antibody design with mutations in the fc domain
RU2013131911A (ru)	2010-12-16	2015-01-27	Ново Нордиск А/С	Водный раствор фактора viii
PL2654794T3 (pl)	2010-12-22	2020-07-27	Baxalta GmbH	Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
AU2012204241A1 (en) *	2011-01-06	2013-06-06	The Johns Hopkins University	Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells
AU2012205301B2 (en)	2011-01-14	2017-01-05	Redwood Bioscience, Inc.	Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
KR20140114278A (ko) *	2011-02-25	2014-09-26	머크 샤프 앤드 돔 코포레이션	변형된 ｏ-글리코실화를 갖는 단백질의 생산을 위한 효모 균주
JP6215056B2 (ja)	2011-03-01	2017-10-18	ノヴォノルディスクアー／エス	拮抗性ｄｒ３リガンド
MX2013009862A (es)	2011-03-02	2013-10-25	Novo Nordisk As	Factor de coagulacion dirigido al transcripto 1 tipo trem (tlt-1) en plaquetas activadas.
CN103732628B (zh)	2011-03-03	2017-06-23	酵活有限公司	多价杂多聚体骨架设计和构建体
EP2895592A1 (en)	2011-03-23	2015-07-22	Société Industrielle Limousine d'Application Biologique (SILAB)	A yeast recombinant cell capable of producing gdp-fucose
TR201905909T4 (tr)	2011-04-19	2019-05-21	Pfizer	Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
WO2012158962A2 (en)	2011-05-18	2012-11-22	Eumederis Pharmaceuticals, Inc.	Improved peptide pharmaceuticals
KR102497726B1 (ko) *	2011-05-18	2023-02-07	메더리스 다이어비티즈, 엘엘씨	인슐린 저항성에 대한 개선된 펩티드 제약
US9765158B2 (en)	2011-05-31	2017-09-19	Probiogen Ag	Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders
WO2012170938A1 (en)	2011-06-08	2012-12-13	Acceleron Pharma Inc.	Compositions and methods for increasing serum half-life
HUE043894T2 (hu)	2011-06-10	2019-09-30	Bioverativ Therapeutics Inc	Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
EP2717917B1 (en)	2011-07-05	2016-04-20	biOasis Technologies Inc	P97-antibody conjugates
AU2012294673B2 (en)	2011-08-05	2015-11-26	Bioasis Technologies Inc.	p97 fragments with transfer activity
AR087433A1 (es) *	2011-08-08	2014-03-26	Merck Sharp & Dohme	Analogos de insulina n-glicosilados
JP6352806B2 (ja)	2011-09-23	2018-07-04	ノヴォノルディスクアー／エス	新規のグルカゴン類似体
RU2636456C2 (ru) *	2011-10-01	2017-11-23	Глитек, Инк.	Гликозилированный полипептид и содержащая его фармацевтическая композиция
KR101456174B1 (ko) *	2011-10-18	2014-11-03	한국생명공학연구원	용해도가 증가된 비―퀴논 젤다나마이신 당전이 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이의 열충격 단백질(Ｈｓｐ90) 에이티피아제(ＡＴＰａｓｅ) 활성 저해용 약학적 조성물
WO2013058582A2 (ko) *	2011-10-18	2013-04-25	한국생명공학연구원	당전이 효소를 이용한 안사마이신 배당체의 제조방법
US9034829B1 (en)	2011-10-27	2015-05-19	Northwestern University	pH-sensitive polymer-drug conjugates for targeted delivery of therapeutics
CN109897103B (zh)	2011-11-04	2024-05-17	酵活英属哥伦比亚有限公司	在Fc结构域中具有突变的稳定异源二聚的抗体设计
JP6383666B2 (ja)	2012-02-15	2018-08-29	バイオベラティブセラピューティクスインコーポレイテッド	組換え第ｖｉｉｉ因子タンパク質
BR112014020694A2 (pt)	2012-02-15	2018-05-08	Amunix Operating Inc.	proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
WO2013126587A1 (en)	2012-02-21	2013-08-29	Cytonics Corporation	Systems, compositions, and methods for transplantation
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CN104411323A (zh)	2012-04-24	2015-03-11	诺和诺德A/S（股份有限公司）	适用于治疗血友病的药物组合物
WO2013083858A1 (en)	2012-04-24	2013-06-13	Novo Nordisk A/S	Compounds suitable for treatment of haemophilia
US9499634B2 (en)	2012-06-25	2016-11-22	Zymeworks Inc.	Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
CN102786030B (zh) *	2012-07-06	2014-03-12	江苏大学	一种通过溶剂处理制备多肽纳米薄膜的方法
CA2878640C (en)	2012-07-13	2023-10-24	Zymeworks Inc.	Multivalent heteromultimer scaffold design and constructs
EP4397768A3 (en)	2012-07-26	2024-12-18	Momenta Pharmaceuticals, Inc.	Glycoproteins with anti-inflammatory properties
CA2880162C (en)	2012-07-31	2023-04-04	Bioasis Technologies, Inc.	Dephosphorylated lysosomal storage disease proteins and methods of use thereof
AU2013306098A1 (en)	2012-08-18	2015-02-12	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
US9790268B2 (en)	2012-09-12	2017-10-17	Genzyme Corporation	Fc containing polypeptides with altered glycosylation and reduced effector function
CA2885796C (en)	2012-09-24	2022-05-03	Allozyne, Inc.	Cell lines
WO2014057068A1 (en)	2012-10-10	2014-04-17	Novo Nordisk Health Care Ag	Liquid pharmaceutical composition of factor vii polypeptide
US9274430B2 (en)	2012-10-10	2016-03-01	Arizona Board Of Regents On Behalf Of Arizona State University	Systems and devices for molecule sensing and method of manufacturing thereof
JP2015533152A (ja)	2012-10-15	2015-11-19	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	第ｖｉｉ因子コンジュゲート
WO2014060401A1 (en)	2012-10-15	2014-04-24	Novo Nordisk Health Care Ag	Coagulation factor vii polypeptides
CA2891929C (en)	2012-11-20	2022-07-19	Eumederis Pharmaceuticals, Inc.	Improved peptide pharmaceuticals
AU2013347975B2 (en) *	2012-11-20	2018-07-26	Mederis Diabetes, Llc	Improved peptide pharmaceuticals for insulin resistance
US9914785B2 (en)	2012-11-28	2018-03-13	Zymeworks Inc.	Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
JP6735561B2 (ja)	2012-12-03	2020-08-05	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
CN103044509B (zh) *	2013-01-05	2015-04-01	宁辉	γ-胞嘧啶核苷-5’-三磷酸二钠结晶化合物、其制备方法及其药物组合物
WO2014125377A2 (en) *	2013-02-13	2014-08-21	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Highly galactosylated anti-her2 antibodies and uses thereof
BR112015019348A2 (pt)	2013-02-13	2017-08-22	Lab Francais Du Fractionnement	Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
KR20160002713A (ko)	2013-02-13	2016-01-08	라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스	고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
EP3424956A1 (en) *	2013-03-11	2019-01-09	Genzyme Corporation	Hyperglycosylated binding polypeptides
EP2970433B1 (en)	2013-03-13	2019-09-18	Bioasis Technologies Inc.	Fragments of p97 and uses thereof
ES2926773T3 (es)	2013-03-15	2022-10-28	Novo Nordisk As	Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular
CA2909581A1 (en)	2013-04-18	2014-10-23	Novo Nordisk A/S	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
LT2991683T (lt) *	2013-05-02	2019-12-27	Glykos Finland Oy	Glikoproteino arba glikano konjugatai su toksine medžiaga
CA2910945A1 (en) *	2013-05-08	2014-11-13	Zymeworks Inc.	Bispecific her2 and her3 antigen binding constructs
EP2996772B1 (en)	2013-05-13	2018-12-19	Momenta Pharmaceuticals, Inc.	Methods for the treatment of neurodegeneration
WO2014210397A1 (en)	2013-06-26	2014-12-31	Academia Sinica	Rm2 antigens and use thereof
EP3013347B1 (en)	2013-06-27	2019-12-11	Academia Sinica	Glycan conjugates and use thereof
WO2015023891A2 (en)	2013-08-14	2015-02-19	Biogen Idec Ma Inc.	Factor viii-xten fusions and uses thereof
CA2922806A1 (en)	2013-08-28	2015-03-05	Cytonics Corporation	Systems, compositions, and methods for transplantation and treating conditions utilizing a composition comprising a wild-type or a variant a2m polypeptide or portion thereof
EP3041484B1 (en)	2013-09-06	2021-03-03	Academia Sinica	Human inkt cell activation using glycolipids with altered glycosyl groups
CN105792852B (zh)	2013-10-04	2019-12-10	默沙东公司	葡萄糖响应性的胰岛素缀合物
EP3058083B1 (en)	2013-10-14	2018-04-11	SynAffix B.V.	Modified glycoprotein, protein-conjugate and process for the preparation thereof
US20160235861A1 (en) *	2013-10-14	2016-08-18	SynAffix. B.V.	Glycoengineered antibody, antibody-conjugate and methods for their preparation
AU2014336252A1 (en)	2013-10-15	2016-04-07	Novo Nordisk Health Care Ag	Coagulation factor VII polypeptides
EP3058084A4 (en)	2013-10-16	2017-07-05	Momenta Pharmaceuticals, Inc.	Sialylated glycoproteins
AU2015206370A1 (en)	2014-01-16	2016-07-07	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10023892B2 (en) *	2014-05-27	2018-07-17	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10266502B2 (en)	2014-01-24	2019-04-23	Synaffix B.V.	Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
EP3925951A1 (en)	2014-01-24	2021-12-22	SynAffix B.V.	Process for the cycloaddition of a(hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne
EP3097200A1 (en) *	2014-01-24	2016-11-30	SynAffix B.V.	Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby
WO2015117121A1 (en)	2014-02-03	2015-08-06	Bioasis Technologies, Inc.	P97 fusion proteins
AR099340A1 (es) *	2014-02-12	2016-07-13	Novo Nordisk As	Conjugados del factor de coagulación ix
CA2935805C (en)	2014-02-19	2023-07-11	Bioasis Technologies, Inc.	P97-ids fusion proteins
WO2015130963A2 (en)	2014-02-27	2015-09-03	Xenetic Biosciences, Inc.	Compositions and methods for administering insulin or insulin-like protein to the brain
HUE061339T2 (hu)	2014-03-19	2023-06-28	Genzyme Corp	Targetáló csoportok helyspecifikus glikotechnikai átalakítása
WO2015148915A1 (en)	2014-03-27	2015-10-01	Academia Sinica	Reactive labelling compounds and uses thereof
AU2015243512B2 (en)	2014-04-08	2020-06-04	University Of Georgia Research Foundation Inc.	Site-specific antibody-drug glycoconjugates and methods
JP6750148B2 (ja) *	2014-04-25	2020-09-02	公益財団法人野口研究所	糖鎖切断抗体の製造方法及び均一糖鎖抗体
US10058619B2 (en)	2014-05-01	2018-08-28	Bioasis Technologies, Inc.	P97-polynucleotide conjugates
US20150344585A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7062361B2 (ja)	2014-05-27	2022-05-06	アカデミアシニカ	抗ｈｅｒ２糖操作抗体群およびその使用
CN106714829A (zh)	2014-05-28	2017-05-24	中央研究院	抗TNF‑α醣抗体及其用途
HUE066179T2 (hu)	2014-05-28	2024-07-28	Mederis Diabetes Llc	Javított peptidek inzulinrezisztencia ellen
US10570184B2 (en)	2014-06-04	2020-02-25	Novo Nordisk A/S	GLP-1/glucagon receptor co-agonists for medical use
DK3160513T3 (da)	2014-06-30	2020-04-06	Glykos Finland Oy	Saccharidderivat af en toksisk payload og antistofkonjugater deraf
EP3166623B1 (en) *	2014-07-10	2020-05-13	Academia Sinica	Multi-drug delivery system and uses thereof
EP3177317B1 (en)	2014-08-04	2020-03-18	CSL Limited	Factor viii formulation
TWI745275B (zh)	2014-09-08	2021-11-11	中央研究院	使用醣脂激活人類ｉＮＫＴ細胞
WO2016057769A2 (en) *	2014-10-09	2016-04-14	Genzyme Corporation	Glycoengineered antibody drug conjugates
SMT202100388T1 (it)	2014-10-24	2021-09-14	Bristol Myers Squibb Co	Polipeptidi fgf-21 modificati e loro usi
US10889631B2 (en)	2014-11-20	2021-01-12	Cytonics Corporation	Therapeutic variant alpha-2-macroglobulin compositions
WO2016091268A2 (en)	2014-12-12	2016-06-16	University Of Copenhagen	N-glycosylation
CN107428813B (zh)	2014-12-31	2021-08-03	查克美特制药公司	组合肿瘤免疫疗法
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
WO2016118191A1 (en)	2015-01-24	2016-07-28	Academia Sinica	Novel glycan conjugates and methods of use thereof
KR20170125941A (ko)	2015-03-06	2017-11-15	체에스엘 베링 리컴비넌트 퍼실리티 아게	개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
FR3038517B1 (fr)	2015-07-06	2020-02-28	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Utilisation de fragments fc modifies en immunotherapie
EA201890423A1 (ru)	2015-08-03	2018-07-31	Биовератив Терапьютикс Инк.	Слитые белки фактора ix, способы их получения и применения
EP4162955A1 (en)	2016-01-08	2023-04-12	Ascendis Pharma Growth Disorders A/S	Cnp prodrugs with carrier attachment at the ring moiety
CA3007976C (en)	2016-01-08	2023-09-26	Ascendis Pharma Growth Disorders A/S	Cnp prodrugs with large carrier moieties
SG11201805026SA (en)	2016-01-08	2018-07-30	Ascendis Pharma Growth Disorders As	Controlled-release cnp agonists with low npr-c binding
SMT202600051T1 (it) *	2016-01-08	2026-03-09	Ascendis Pharma Growth Disorders As	Agonisti del cnp a rilascio controllato con effetti collaterali ridotti
EP3400022A1 (en)	2016-01-08	2018-11-14	Ascendis Pharma Growth Disorders A/S	Controlled-release cnp agonists with low initial npr-b activity
CN108472380B (zh)	2016-01-08	2022-03-01	阿森迪斯药物生长障碍股份有限公司	具有增加的nep稳定性的控制释放cnp激动剂
CN105505884B (zh) *	2016-01-26	2017-10-03	郑州师范学院	进行抗体表达和组装的重组系统及应用
WO2017156192A1 (en)	2016-03-08	2017-09-14	Academia Sinica	Methods for modular synthesis of n-glycans and arrays thereof
US20170360905A1 (en) *	2016-04-04	2017-12-21	Shire Human Genetic Therapies, Inc.	Conjugated C1 Esterase Inhibitor and Uses Thereof
CA3019398A1 (en)	2016-04-26	2017-11-02	R.P. Scherer Technologies, Llc	Antibody conjugates and methods of making and using the same
KR20220119529A (ko)	2016-06-02	2022-08-29	애브비 인코포레이티드	글루코코르티코이드 수용체 작용제 및 이의 면역접합체
TWI764917B (zh)	2016-08-22	2022-05-21	醣基生醫股份有限公司	抗體、結合片段及使用方法
LT3518930T (lt)	2016-09-29	2023-05-10	Ascendis Pharma Growth Disorders A/S	Kompleksinė terapija su kontroliuojamo išskyrimo cnp agonistais
KR20260008164A (ko)	2016-12-02	2026-01-15	바이오버라티브 테라퓨틱스 인크.	키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
JP6852397B2 (ja) *	2016-12-28	2021-03-31	株式会社島津製作所	分析用試料の調製方法および分析方法
CA3048452C (en) *	2016-12-29	2021-06-15	Development Center For Biotechnology	Processes for preparing glycoprotein-drug conjugates
US10266578B2 (en)	2017-02-08	2019-04-23	Bristol-Myers Squibb Company	Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
EP4169937A1 (en)	2017-02-17	2023-04-26	Denali Therapeutics Inc.	Engineered transferrin receptor binding polypeptides
JP2020511499A (ja)	2017-03-20	2020-04-16	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法
CA3069321A1 (en)	2017-07-11	2019-01-17	The Scripps Research Institute	Incorporation of unnatural nucleotides and methods thereof
KR20250145137A (ko)	2017-08-03	2025-10-13	신톡스, 인크.	자가면역 질환의 치료를 위한 사이토카인 접합체
EP3678687B1 (en)	2017-09-04	2022-08-17	89Bio Ltd.	Mutant fgf-21 peptide conjugates and uses thereof
PH12020550661A1 (en)	2017-11-21	2021-04-19	Univ Leland Stanford Junior	Partial agonists of interleukin-2
WO2019106609A1 (en)	2017-12-01	2019-06-06	Abbvie Inc.	Glucocorticoid receptor agonist and immunoconjugates thereof
PT3735295T (pt)	2018-01-03	2024-12-11	Mederis Diabetes Llc	Farmacêuticos peptídicos melhorados para tratamento de nash e outras disfunções
EP3752194A4 (en)	2018-02-13	2022-03-16	Checkmate Pharmaceuticals, Inc.	COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
KR102890791B1 (ko)	2018-04-09	2025-11-24	체크메이트 파마슈티칼스, 인크.	바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
MA52630B1 (fr)	2018-05-18	2025-07-31	Bioverativ Therapeutics Inc.	Procédés de traitement de l'hémophilie a
EP3796941A4 (en) *	2018-05-30	2022-12-28	Purdue Research Foundation	Targeting anabolic drugs for accelerated fracture repair
CN113301925A (zh)	2018-12-19	2021-08-24	小利兰·斯坦福大学理事会	用于溶酶体靶向的双官能分子以及相关的组合物和方法
SG11202107354WA (en)	2019-02-06	2021-08-30	Synthorx Inc	Il-2 conjugates and methods of use thereof
EP3923906A1 (en)	2019-02-11	2021-12-22	Ascendis Pharma Growth Disorders A/S	Dry pharmaceutical formulations of cnp conjugates
JP7780341B2 (ja)	2019-07-04	2025-12-04	ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト	第ＶＩＩＩ凝固因子のｉｎｖｉｔｒｏでの安定性を向上させるための切断型フォン・ヴィレブランド因子（ＶＷＦ）
US20220348637A1 (en)	2019-11-11	2022-11-03	CSL Behring Lengnau AG	Polypeptides for inducing tolerance to factor viii
MX2022007486A (es)	2019-12-23	2022-06-29	Denali Therapeutics Inc	Variantes de progranulina.
EP4090674A4 (en)	2020-01-14	2024-01-24	Synthekine, Inc.	Biased il2 muteins methods and compositions
US12122845B2 (en) *	2020-08-07	2024-10-22	Eutilex Co., Ltd.	Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof
US20230235082A1 (en) *	2020-08-21	2023-07-27	Glyco-Therapy Biotechnology Co., Ltd.	Site-specific antibody conjugates and the methods for preparation of the same
WO2022079211A1 (en) *	2020-10-16	2022-04-21	Adc Therapeutics Sa	Glycoconjugates
MX2023004395A (es) *	2020-10-16	2023-05-22	Univ Georgia	Glicoconjugados.
CN117202924A (zh)	2020-12-07	2023-12-08	斯皮特弗尔制药有限责任公司	使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
WO2022136705A1 (en) *	2020-12-24	2022-06-30	Synaffix B.V.	Glycan-conjugated antibodies binding to fc-gamma receptor
EP4279089A4 (en) *	2021-02-22	2025-10-22	Shanghai Inst Materia Medica Cas	DISACCHARIDE LINKER, SMALL MOLECULE DRUG-DISACCHARIDE CONJUGATE AND SUGAR CHAIN FIXED POINT ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD AND USE THEREOF
CN113429443B (zh) *	2021-07-08	2023-07-25	江南大学	一种双唾液酸-甘露寡糖复合物及其合成方法
CA3226269A1 (en)	2021-07-14	2023-01-19	Lycia Therapeutics, Inc.	Asgpr cell surface receptor binding compounds and conjugates
EP4225766A4 (en) *	2021-12-20	2024-03-27	89Bio, Inc.	CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID
EP4285934A1 (en)	2022-05-30	2023-12-06	CER Groupe	Modified trimannose-oligosacharides, bisected n-glycans comprising said trimannose core and method for obtaining them
AU2023287799A1 (en)	2022-06-24	2024-11-21	89Bio Inc.	Compositions and methods of treatment for severe hypertriglyceridemia
JP2026501620A (ja) *	2022-12-29	2026-01-16	嘉正生物科技股▲分▼有限公司	糖タンパク質を修飾する方法

Family Cites Families (296)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3691016A (en)	1970-04-17	1972-09-12	Monsanto Co	Process for the preparation of insoluble enzymes
CA1023287A (en)	1972-12-08	1977-12-27	Boehringer Mannheim G.M.B.H.	Process for the preparation of carrier-bound proteins
GB1479268A (en)	1973-07-05	1977-07-13	Beecham Group Ltd	Pharmaceutical compositions
DE2433883C2 (de) *	1973-07-20	1986-03-27	Research Corp., New York, N.Y.	Verwendung von physiologisch aktiven Polypeptiden
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
CH596313A5 (da)	1975-05-30	1978-03-15	Battelle Memorial Institute
US4385260A (en) *	1975-09-09	1983-05-24	Beckman Instruments, Inc.	Bargraph display
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4342832A (en)	1979-07-05	1982-08-03	Genentech, Inc.	Method of constructing a replicable cloning vehicle having quasi-synthetic genes
IL63270A0 (en)	1980-08-05	1981-10-30	Univ Leland Stanford Junior	Eukaryotic autonomously replicating segment
US4414147A (en)	1981-04-17	1983-11-08	Massachusetts Institute Of Technology	Methods of decreasing the hydrophobicity of fibroblast and other interferons
JPS57206622A (en) *	1981-06-10	1982-12-18	Ajinomoto Co Inc	Blood substitute
US4579821A (en)	1981-11-23	1986-04-01	University Patents, Inc.	Control of DNA sequence transcription
US4656134A (en)	1982-01-11	1987-04-07	Board Of Trustees Of Leland Stanford Jr. University	Gene amplification in eukaryotic cells
US4975276A (en)	1982-01-15	1990-12-04	Cetus Corporation	Interferon-alpha 54
US4748233A (en)	1982-03-23	1988-05-31	Bristol-Myers Company	Alpha-interferon Gx-1
US4695543A (en)	1982-03-23	1987-09-22	Bristol-Myers Company	Alpha Interferon GX-1
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
ATE42338T1 (de)	1982-05-19	1989-05-15	Unilever Nv	Hefe des genus kluyveromyces, modifiziert zur expression von preprothaumatin oder seinen verschiedenen allelischen und modifizierten formen oder maturationsformen.
US4486533A (en)	1982-09-02	1984-12-04	St. Louis University	Filamentous fungi functional replicating extrachromosomal element
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4599311A (en)	1982-08-13	1986-07-08	Kawasaki Glenn H	Glycolytic promotersfor regulated protein expression: protease inhibitor
US5151511A (en)	1982-09-16	1992-09-29	Amgen Inc.	DNA encoding avian growth hormones
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4737462A (en)	1982-10-19	1988-04-12	Cetus Corporation	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4966843A (en)	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
US4438253A (en)	1982-11-12	1984-03-20	American Cyanamid Company	Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
US4603044A (en)	1983-01-06	1986-07-29	Technology Unlimited, Inc.	Hepatocyte Directed Vesicle delivery system
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US4713339A (en)	1983-01-19	1987-12-15	Genentech, Inc.	Polycistronic expression vector construction
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
US4745051A (en)	1983-05-27	1988-05-17	The Texas A&M University System	Method for producing a recombinant baculovirus expression vector
US4923805A (en)	1983-11-02	1990-05-08	Integrated Genetics, Inc.	Fsh
US5156957A (en)	1983-11-02	1992-10-20	Genzyme Corporation	Follicle stimulating hormone
US5639639A (en)	1983-11-02	1997-06-17	Genzyme Corporation	Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4840896A (en)	1983-11-02	1989-06-20	Integrated Genetics, Inc.	Heteropolymeric protein
US4758656A (en)	1983-12-26	1988-07-19	Kyowa Hakko Kogyo Co., Ltd.	Novel human interferon-gamma polypeptide derivative
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en)	1984-03-06	1989-10-19	Takeda Chemical Industries Ltd	Chemically modified lymphokine and production thereof
US4965199A (en)	1984-04-20	1990-10-23	Genentech, Inc.	Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
IL71691A (en)	1984-04-27	1991-04-15	Yeda Res & Dev	Production of interferon-ypsilon
US4879236A (en)	1984-05-16	1989-11-07	The Texas A&M University System	Method for producing a recombinant baculovirus expression vector
US4931373A (en)	1984-05-25	1990-06-05	Zymogenetics, Inc.	Stable DNA constructs for expression of α-1 antitrypsin
US4589402A (en)	1984-07-26	1986-05-20	Serono Laboratories, Inc.	Method of in vitro fertilization
US4970300A (en) *	1985-02-01	1990-11-13	New York University	Modified factor VIII
US4761371A (en)	1985-02-12	1988-08-02	Genentech, Inc.	Insulin receptor
US5034506A (en)	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
GR860984B (en)	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
ATE74164T1 (de)	1985-04-22	1992-04-15	Genetics Inst	Herstellung mit hoher leistung des aktivfaktors ix.
ATE36690T1 (de)	1985-04-30	1988-09-15	Buero Patent Ag	Anlage und verfahren zum automatischen zufuehren von vollen kannen zu und zum abfuehren leerer kannen von spinnstellen einer spinnmaschine.
WO1987000056A1 (en)	1985-06-26	1987-01-15	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JPS6238172A (ja)	1985-08-12	1987-02-19	株式会社　高研	抗血栓性医用材料の製造方法
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en)	1985-08-23	1999-12-21	Amgen, Inc.	Analogs of pluripotent granulocyte colony-stimulating factor
JPH0657152B2 (ja)	1985-09-17	1994-08-03	中外製薬株式会社	Ｃｓｆ遺伝子類
EP0238655A4 (en)	1985-10-03	1989-09-11	Biogen Nv	POLYPEPTIDES LIKE THE GRANULOCYTE-MACROPHOUS COLONY STIMULATION FACTORS (GM-CSF) AND THEIR METHODS OF PRODUCING LARGE QUANTITIES IN MICROBIAL CELLS.
IL80529A0 (en)	1985-11-14	1987-02-27	Daiichi Seiyaku Co	Method of producing peptides
DE3712985A1 (de)	1987-04-16	1988-11-03	Hoechst Ag	Bifunktionelle proteine
US4935349A (en)	1986-01-17	1990-06-19	Zymogenetics, Inc.	Expression of higher eucaryotic genes in aspergillus
JPS63502716A (ja)	1986-03-07	1988-10-13	マサチューセッツ・インステチュート・オブ・テクノロジー	糖タンパク安定性の強化方法
US4925796A (en) *	1986-03-07	1990-05-15	Massachusetts Institute Of Technology	Method for enhancing glycoprotein stability
IT1203758B (it)	1986-03-27	1989-02-23	Univ Roma	Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori
GB8610600D0 (en)	1986-04-30	1986-06-04	Novo Industri As	Transformation of trichoderma
US4902505A (en)	1986-07-30	1990-02-20	Alkermes	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5075109A (en)	1986-10-24	1991-12-24	Southern Research Institute	Method of potentiating an immune response
US4894330A (en)	1986-12-23	1990-01-16	Cetus Corporation	Purification of recombinant beta-interferon incorporating RP-HPLC
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4857505A (en) *	1987-03-09	1989-08-15	American Cyanamid Company	Sustained release compositions for parenteral administration and their use
ATE103333T1 (de)	1987-03-23	1994-04-15	Zymogenetics Inc	Hohe proteinsyntheserate in hefe.
US5149637A (en)	1987-04-06	1992-09-22	Scripps Clinic & Research Foundation	Recombinant Factor VIIIC fragments
DE3712564A1 (de) *	1987-04-14	1988-11-24	Bioferon Biochem Substanz	Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
IL82834A (en)	1987-06-09	1990-11-05	Yissum Res Dev Co	Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom
HU208553B (en)	1987-07-28	1993-11-29	Gist Brocades Nv	Process for producing polypeptides, plasmides coding them and transformed kluyveromyces
US4897268A (en)	1987-08-03	1990-01-30	Southern Research Institute	Drug delivery system and method of making the same
US5252726A (en)	1987-09-04	1993-10-12	Novo Nordisk A/S	Promoters for use in aspergillus
GB8725529D0 (en)	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
US5153265A (en) *	1988-01-20	1992-10-06	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
US4847325A (en) *	1988-01-20	1989-07-11	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
GB8810808D0 (en)	1988-05-06	1988-06-08	Wellcome Found	Vectors
JP2511494B2 (ja)	1988-05-12	1996-06-26	善治松浦	日本脳炎ウイルス表面抗原蛋白質の製造法
US5770198A (en)	1988-05-18	1998-06-23	The Research Foundation Of The State Of New York	Platelet-specific chimeric 7E3 immunoglobulin
FR2631974B1 (fr)	1988-05-31	1992-12-11	Agronomique Inst Nat Rech	Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
FR2649991B2 (fr)	1988-08-05	1994-03-04	Rhone Poulenc Sante	Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5162215A (en)	1988-09-22	1992-11-10	Amgen Inc.	Method of gene transfer into chickens and other avian species
US5218092A (en) *	1988-09-29	1993-06-08	Kyowa Hakko Kogyo Co., Ltd.	Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5534617A (en)	1988-10-28	1996-07-09	Genentech, Inc.	Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
FR2638643B1 (fr)	1988-11-09	1991-04-12	Transgene Sa	Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US5047335A (en)	1988-12-21	1991-09-10	The Regents Of The University Of Calif.	Process for controlling intracellular glycosylation of proteins
US6166183A (en)	1992-11-30	2000-12-26	Kirin-Amgen, Inc.	Chemically-modified G-CSF
WO1990007572A1 (en)	1988-12-23	1990-07-12	Genentech, Inc.	HUMAN DNase
US5162228A (en)	1988-12-28	1992-11-10	Takeda Chemical Industries, Ltd.	Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5198346A (en)	1989-01-06	1993-03-30	Protein Engineering Corp.	Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en)	1989-01-06	1992-03-17	Protein Engineering Corporation	Generation and selection of novel dna-binding proteins and polypeptides
US4957773A (en)	1989-02-13	1990-09-18	Syracuse University	Deposition of boron-containing films from decaborane
US5338835A (en)	1989-02-21	1994-08-16	Washington University	CTP-extended form of FSH
US5475090A (en)	1989-02-21	1995-12-12	Boyce Thompson Institute For Plant Research	Gene coded for a polypeptide which enhances virus infection of host insects
US5194376A (en)	1989-02-28	1993-03-16	University Of Ottawa	Baculovirus expression system capable of producing foreign gene proteins at high levels
DE3906540A1 (de)	1989-03-02	1990-09-13	Behringwerke Ag	Expressionsvektoren zur synthese von proteinen in der spalthefe schizosaccharomyces pombe
US5179023A (en)	1989-03-24	1993-01-12	Research Corporation Technologies, Inc.	Recombinant α-galactosidase a therapy for Fabry disease
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en)	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
ES2247656T3 (es)	1989-04-19	2006-03-01	Enzon, Inc.	Un proceso para formar un polipeptido modificado que comprende un polipeptido y un oxido de polialquileno.
DE68927344T2 (de)	1989-04-28	1997-02-20	Rhein Biotech Proz & Prod Gmbh	Hefezellen der Gattung-Schwanniomyces
US5766883A (en)	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
US5244805A (en)	1989-05-17	1993-09-14	University Of Georgia Research Foundation, Inc.	Baculovirus expression vectors
US5077214A (en)	1989-07-07	1991-12-31	The Texas A&M University System	Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5162222A (en)	1989-07-07	1992-11-10	Guarino Linda A	Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5179007A (en)	1989-07-07	1993-01-12	The Texas A & M University System	Method and vector for the purification of foreign proteins
FR2650598B1 (fr)	1989-08-03	1994-06-03	Rhone Poulenc Sante	Derives de l'albumine a fonction therapeutique
US5155037A (en)	1989-08-04	1992-10-13	The Texas A&M University System	Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5023328A (en)	1989-08-04	1991-06-11	The Texas A&M University System	Lepidopteran AKH signal sequence
US5527527A (en)	1989-09-07	1996-06-18	Alkermes, Inc.	Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en)	1989-09-07	1997-09-30	Alkermes, Inc.	Transferrin neuropharmaceutical agent fusion protein
US5977307A (en)	1989-09-07	1999-11-02	Alkermes, Inc.	Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5182107A (en)	1989-09-07	1993-01-26	Alkermes, Inc.	Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5154924A (en)	1989-09-07	1992-10-13	Alkermes, Inc.	Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5032519A (en)	1989-10-24	1991-07-16	The Regents Of The Univ. Of California	Method for producing secretable glycosyltransferases and other Golgi processing enzymes
US5580560A (en) *	1989-11-13	1996-12-03	Novo Nordisk A/S	Modified factor VII/VIIa
US5312808A (en)	1989-11-22	1994-05-17	Enzon, Inc.	Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
FR2657884B1 (fr)	1990-02-05	1994-09-02	Tm Innovation	Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
DE4009630C2 (de) *	1990-03-26	1995-09-28	Reinhard Prof Dr Dr Brossmer	CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung
JP2975632B2 (ja) *	1990-03-30	1999-11-10	生化学工業株式会社	グリコサミノグリカン修飾プロテイン
US5606031A (en)	1990-04-06	1997-02-25	Lile; Jack	Production and purification of biologically active recombinant neurotrophic protein in bacteria
GB9107846D0 (en)	1990-04-30	1991-05-29	Ici Plc	Polypeptides
US5951972A (en) *	1990-05-04	1999-09-14	American Cyanamid Company	Stabilization of somatotropins and other proteins by modification of cysteine residues
US5399345A (en)	1990-05-08	1995-03-21	Boehringer Mannheim, Gmbh	Muteins of the granulocyte colony stimulating factor
US5219564A (en)	1990-07-06	1993-06-15	Enzon, Inc.	Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
JPH06502987A (ja) *	1990-07-10	1994-04-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｏ―グリコシル化ｉｆｎ―アルファ
FR2664905B1 (fr)	1990-07-18	1994-08-12	Agronomique Inst Nat Rech	Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5169784A (en)	1990-09-17	1992-12-08	The Texas A & M University System	Baculovirus dual promoter expression vector
US5529914A (en)	1990-10-15	1996-06-25	The Board Of Regents The Univeristy Of Texas System	Gels for encapsulation of biological materials
US5410016A (en)	1990-10-15	1995-04-25	Board Of Regents, The University Of Texas System	Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5401650A (en)	1990-10-24	1995-03-28	The Mount Sinai School Of Medicine Of The City University Of New York	Cloning and expression of biologically active α-galactosidase A
GB9023111D0 (en)	1990-10-24	1990-12-05	Wellcome Found	Expression system
EP0513332A4 (en) *	1990-11-14	1993-03-17	Cargill, Incorporated	Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
US5420027A (en)	1991-01-10	1995-05-30	Board Of Regents, The University Of Texas System	Methods and compositions for the expression of biologically active fusion proteins comprising a eukaryotic cytochrome P450 fused to a reductase in bacteria
US6288304B1 (en)	1991-02-22	2001-09-11	Sembiosys Genetics Inc.	Expression of somatotropin in plant seeds
US5650554A (en)	1991-02-22	1997-07-22	Sembiosys Genetics Inc.	Oil-body proteins as carriers of high-value peptides in plants
US5948682A (en)	1991-02-22	1999-09-07	Sembiosys Genetics Inc.	Preparation of heterologous proteins on oil bodies
US5788965A (en)	1991-02-28	1998-08-04	Novo Nordisk A/S	Modified factor VII
US5833982A (en)	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
US5817788A (en)	1991-02-28	1998-10-06	Zymogenetics, Inc.	Modified factor VII
US5861374A (en)	1991-02-28	1999-01-19	Novo Nordisk A/S	Modified Factor VII
US5997864A (en)	1995-06-07	1999-12-07	Novo Nordisk A/S	Modified factor VII
US5661008A (en)	1991-03-15	1997-08-26	Kabi Pharmacia Ab	Recombinant human factor VIII derivatives
DE69231127D1 (de)	1991-03-18	2000-07-06	Scripps Research Inst La Jolla	Oligosaccharide als enzymsubstrate und -inhibitoren: verfahren und zusammensetzungen
US5278299A (en) *	1991-03-18	1994-01-11	Scripps Clinic And Research Foundation	Method and composition for synthesizing sialylated glycosyl compounds
US5212075A (en)	1991-04-15	1993-05-18	The Regents Of The University Of California	Compositions and methods for introducing effectors to pathogens and cells
US5472858A (en)	1991-06-04	1995-12-05	Wisconsin Alumni Research Foundation	Production of recombinant proteins in insect larvae
US5352670A (en)	1991-06-10	1994-10-04	Alberta Research Council	Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
US5374655A (en)	1991-06-10	1994-12-20	Alberta Research Council	Methods for the synthesis of monofucosylated oligosaccharides terminating in di-N-acetyllactosaminyl structures
KR950014915B1 (ko) *	1991-06-19	1995-12-18	주식회사녹십자	탈시알로당단백-포함화합물
US5352570A (en)	1991-06-28	1994-10-04	Eastman Kodak Company	Method and photographic material and process comprising a benzotriazole compound
AU2147192A (en) *	1991-06-28	1993-01-25	Genentech Inc.	Method of stimulating immune response using growth hormone
US5633146A (en)	1991-07-02	1997-05-27	Rhone-Poulenc Rorer S.A.	Method for producing recombinant proteins and host cells used therein
US5281698A (en)	1991-07-23	1994-01-25	Cetus Oncology Corporation	Preparation of an activated polymer ester for protein conjugation
US5777085A (en)	1991-12-20	1998-07-07	Protein Design Labs, Inc.	Humanized antibodies reactive with GPIIB/IIIA
DK8892D0 (da)	1992-01-23	1992-01-23	Symbicom Ab	Humant proteingen
IT1260468B (it)	1992-01-29	1996-04-09		Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
US6039944A (en)	1992-02-28	2000-03-21	Zymogenetics, Inc.	Modified Factor VII
US5965106A (en)	1992-03-04	1999-10-12	Perimmune Holdings, Inc.	In vivo binding pair pretargeting
ES2187505T3 (es)	1992-04-02	2003-06-16	Sembiosys Genetics Inc	Elementos cis de proteinas de cuerpo oleoso como señales reguladoras.
US6037452A (en) *	1992-04-10	2000-03-14	Alpha Therapeutic Corporation	Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5516657A (en)	1992-05-11	1996-05-14	Cambridge Biotech Corporation	Baculovirus vectors for expression of secretory and membrane-bound proteins
US5614184A (en) *	1992-07-28	1997-03-25	New England Deaconess Hospital	Recombinant human erythropoietin mutants and therapeutic methods employing them
CA2141673A1 (en) *	1992-08-07	1994-02-17	Graham P. Allaway	Non-peptidyl moiety-conjugated cd4-gamma2 and cd4-igg2 immunoconjugates, and uses thereof
AU5006993A (en)	1992-08-21	1994-03-15	Enzon, Inc.	Novel attachment of polyalkylene oxides to bio-effecting substances
AU5098193A (en)	1992-09-01	1994-03-29	Berlex Laboratories, Inc.	Glycolation of glycosylated macromolecules
US5348886A (en)	1992-09-04	1994-09-20	Monsanto Company	Method of producing recombinant eukaryotic viruses in bacteria
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1994012646A1 (en)	1992-11-27	1994-06-09	Ciba-Geigy Ag	Proteins having glycosyltransferase activity
US6210671B1 (en)	1992-12-01	2001-04-03	Protein Design Labs, Inc.	Humanized antibodies reactive with L-selectin
NZ250375A (en) *	1992-12-09	1995-07-26	Ortho Pharma Corp	Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
AU6029594A (en)	1993-01-15	1994-08-15	Enzon, Inc.	Factor viii - polymeric conjugates
US5349001A (en)	1993-01-19	1994-09-20	Enzon, Inc.	Cyclic imide thione activated polyalkylene oxides
US5321095A (en)	1993-02-02	1994-06-14	Enzon, Inc.	Azlactone activated polyalkylene oxides
US5202413A (en)	1993-02-16	1993-04-13	E. I. Du Pont De Nemours And Company	Alternating (ABA)N polylactide block copolymers
AUPN154295A0 (en)	1995-03-06	1995-03-30	Commonwealth Scientific And Industrial Research Organisation	Nucleic acid molecule encoding a protein with avian gamma-interferon activity
US5374541A (en)	1993-05-04	1994-12-20	The Scripps Research Institute	Combined use of β-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides
US6174530B1 (en)	1993-05-05	2001-01-16	Gryphon Sciences	Homogeneous polyoxime compositions and their preparation by parallel assembly
US6001364A (en)	1993-05-05	1999-12-14	Gryphon Sciences	Hetero-polyoxime compounds and their preparation by parallel assembly
WO1994028024A1 (en) *	1993-06-01	1994-12-08	Enzon, Inc.	Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) *	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
EP0785988A1 (en) *	1993-07-15	1997-07-30	Neose Pharmaceuticals, Inc	Method of synthesizing saccharide compositions
DE4325317C2 (de) *	1993-07-29	1998-05-20	Univ Dresden Tech	Verfahren zur radioaktiven Markierung von Immunglobulinen
JPH0770195A (ja) *	1993-08-23	1995-03-14	Yutaka Mizushima	糖修飾インターフェロン
US5446090A (en)	1993-11-12	1995-08-29	Shearwater Polymers, Inc.	Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
CA2179394A1 (en)	1993-12-23	1995-06-29	Kostas Iatrou	Methods of expressing proteins in insect cells and methods of killing insects
US5597709A (en)	1994-01-27	1997-01-28	Human Genome Sciences, Inc.	Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
US5369017A (en) *	1994-02-04	1994-11-29	The Scripps Research Institute	Process for solid phase glycopeptide synthesis
US6117679A (en)	1994-02-17	2000-09-12	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US6165793A (en)	1996-03-25	2000-12-26	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US5545723A (en)	1994-03-15	1996-08-13	Biogen Inc.	Muteins of IFN-β
JP3090586B2 (ja)	1994-03-15	2000-09-25	片倉工業株式会社	システインプロテアーゼ遺伝子欠損バキュロウイルスおよびその製造法並びにこれを利用する有用タンパク質の製造法
US5432059A (en)	1994-04-01	1995-07-11	Specialty Laboratories, Inc.	Assay for glycosylation deficiency disorders
GB9408717D0 (en)	1994-05-03	1994-06-22	Biotech & Biolog Scien Res	DNA sequences
DE69526395D1 (de)	1994-08-13	2002-05-23	Roche Diagnostics Gmbh	Verwendung von Interferon-gamma zur Vermeidung der Proliferation und Differenzierung der primitiven Hämapoietischen Vorläuferzellen
US5871986A (en)	1994-09-23	1999-02-16	The General Hospital Corporation	Use of a baculovirus to express and exogenous gene in a mammalian cell
US5545553A (en)	1994-09-26	1996-08-13	The Rockefeller University	Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
EP0785276A4 (en) *	1994-09-29	2002-01-09	Ajinomoto Kk	MODIFICATION OF A PEPTIDE AND A PROTEIN
US5521299A (en)	1994-11-22	1996-05-28	National Science Council	Oligonucleotides for detection of baculovirus infection
US5834251A (en) *	1994-12-30	1998-11-10	Alko Group Ltd.	Methods of modifying carbohydrate moieties
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL116730A0 (en) *	1995-01-13	1996-05-14	Amgen Inc	Chemically modified interferon
US6287557B1 (en)	1995-02-21	2001-09-11	Cantab Pharmaceuticals Research Limited	Methods of gene therapy using herpes viral vectors expressing GM-CSF
US5843705A (en)	1995-02-21	1998-12-01	Genzyme Transgenic Corporation	Transgenically produced antithrombin III
GB9506249D0 (en)	1995-03-27	1995-05-17	Karobio Ab	Media for insect cell cultures
US5728554A (en)	1995-04-11	1998-03-17	Cytel Corporation	Enzymatic synthesis of glycosidic linkages
US5922577A (en)	1995-04-11	1999-07-13	Cytel Corporation	Enzymatic synthesis of glycosidic linkages
US5876980A (en)	1995-04-11	1999-03-02	Cytel Corporation	Enzymatic synthesis of oligosaccharides
US6030815A (en)	1995-04-11	2000-02-29	Neose Technologies, Inc.	Enzymatic synthesis of oligosaccharides
AU5920096A (en) *	1995-05-15	1996-11-29	Constantin A. Bona	Carbohydrate-mediated coupling of peptides to immunoglobulins
US6015555A (en)	1995-05-19	2000-01-18	Alkermes, Inc.	Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5770191A (en)	1995-05-24	1998-06-23	University Of Florida	Active C-terminal peptides of interferon--gamma and their use
WO1996040731A1 (en)	1995-06-07	1996-12-19	Mount Sinai School Of Medicine Of The City University Of New York	Pegylated modified proteins
US5858752A (en) *	1995-06-07	1999-01-12	The General Hospital Corporation	Fucosyltransferase genes and uses thereof
US5672662A (en)	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5811634A (en)	1995-09-12	1998-09-22	Thomas G. O'Brien	Transgenic mammal encoding ornithine decarboxylase
CA2230492C (en) *	1995-09-21	2009-05-26	Genentech, Inc.	Human growth hormone variants
SE9503380D0 (sv) *	1995-09-29	1995-09-29	Pharmacia Ab	Protein derivatives
US5767379A (en)	1995-11-06	1998-06-16	John Howard	Commercial production of avidin in plants
WO1997017451A2 (en)	1995-11-09	1997-05-15	Zymogenetics, Inc.	Production of gad65 in methylotrophic yeast
US6171820B1 (en)	1995-12-07	2001-01-09	Diversa Corporation	Saturation mutagenesis in directed evolution
US6361974B1 (en)	1995-12-07	2002-03-26	Diversa Corporation	Exonuclease-mediated nucleic acid reassembly in directed evolution
US5965408A (en)	1996-07-09	1999-10-12	Diversa Corporation	Method of DNA reassembly by interrupting synthesis
US5716812A (en)	1995-12-12	1998-02-10	The University Of British Columbia	Methods and compositions for synthesis of oligosaccharides, and the products formed thereby
US5728580A (en)	1996-02-20	1998-03-17	Cornell Research Foundation, Inc.	Methods and culture media for inducing single cell suspension in insect cell lines
US6096548A (en)	1996-03-25	2000-08-01	Maxygen, Inc.	Method for directing evolution of a virus
AT403765B (de)	1996-04-12	1998-05-25	Immuno Ag	Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
US5734024A (en)	1996-04-19	1998-03-31	Boris Y. Zaslavsky	Method for determining the biological activity of recombinant human growth hormone
US5750383A (en)	1996-05-14	1998-05-12	Boyce Thompson Institute For Plant Research, Inc.	Baculovirus cloning system
CA2261151C (en)	1996-07-17	2003-09-16	Zymogenetics, Inc.	Transformation of pichia methanolica
AU708572B2 (en)	1996-07-17	1999-08-05	Zymogenetics Inc.	Preparation of (pichia methanolica) auxotrophic mutants
US5682823A (en)	1996-08-23	1997-11-04	Bethlehem Steel Corporation	Removable insulated cover and method for transporting hot oversized steel ingots
US20020064546A1 (en)	1996-09-13	2002-05-30	J. Milton Harris	Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6454946B1 (en)	1996-10-10	2002-09-24	Neose Technologies, Inc.	Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration
US5856452A (en)	1996-12-16	1999-01-05	Sembiosys Genetics Inc.	Oil bodies and associated proteins as affinity matrices
BR9606270A (pt)	1996-12-18	1998-09-22	Univ Minas Gerais	Processo para a produção da proteína do interferon beta-cis humano recombinante e proteína de interferon beta-cis humano recombinante
DK1015622T3 (da)	1997-01-16	2004-08-02	Neose Technologies Inc	Praktisk sialylering in vitro af rekombinante glycoproteiner
US5945314A (en) *	1997-03-31	1999-08-31	Abbott Laboratories	Process for synthesizing oligosaccharides
US5804420A (en)	1997-04-18	1998-09-08	Bayer Corporation	Preparation of recombinant Factor VIII in a protein free medium
US6183738B1 (en) *	1997-05-12	2001-02-06	Phoenix Pharamacologics, Inc.	Modified arginine deiminase
US7585645B2 (en)	1997-05-27	2009-09-08	Sembiosys Genetics Inc.	Thioredoxin and thioredoxin reductase containing oil body based products
ATE285415T1 (de)	1997-06-13	2005-01-15	Gryphon Therapeutics Inc	Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
US6210736B1 (en)	1997-06-17	2001-04-03	Genzyme Transgenics Corporation	Transgenically produced prolactin
CA2293829C (en)	1997-06-24	2011-06-14	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
AU8269898A (en)	1997-06-27	1999-01-19	Regents Of The University Of California, The	Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
US6090584A (en)	1997-08-21	2000-07-18	University Technologies International Inc.	Baculovirus artificial chromosomes and methods of use
GB9722604D0 (en) *	1997-10-28	1997-12-24	Cancer Res Campaign Tech	Heparin-binding growth factor derivatives
DE69840412D1 (de)	1997-10-31	2009-02-12	Genentech Inc	Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6168937B1 (en)	1997-12-08	2001-01-02	Alan D. Elbein	Purified β1,2-xylosyltransferase and uses thereof
US7244601B2 (en)	1997-12-15	2007-07-17	National Research Council Of Canada	Fusion proteins for use in enzymatic synthesis of oligosaccharides
US6362276B1 (en)	1998-01-07	2002-03-26	Debio Recherche Pharmaceutique S.A.	Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
AU2559799A (en) *	1998-01-22	1999-08-09	Genentech Inc.	Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
AR014491A1 (es)	1998-01-29	2001-02-28	Dow Agrosciences Llc	Metodo para obtener plantas transgenicas fertiles de gossypium hirsutum.
US6362254B2 (en)	1998-03-12	2002-03-26	Shearwater Corporation	Poly(ethylene glycol) derivatives with proximal reactive groups
US6689604B1 (en)	1998-03-20	2004-02-10	National Research Council Of Canada	Lipopolysaccharide α-2,3 sialyltransferase of Campylobacter jejuni and its uses
EP1071700B1 (en)	1998-04-20	2010-02-17	GlycArt Biotechnology AG	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP1117808B1 (en)	1998-10-06	2004-12-29	Mark Aaron Emalfarb	Transformation system in the field of filamentous fungal hosts: in chrysosporium
US6245539B1 (en)	1998-10-06	2001-06-12	Board Of Trustees Operating Michigan State University	Human asparaginyl-tRNA synthetase DNA
HK1042434B (zh) *	1998-10-16	2008-01-25	生物基因Ma公司	干扰素-β-1A的聚合物缀合物及其使用
US6374295B2 (en) *	1998-10-29	2002-04-16	Nortel Networks Limited	Active server management
DE19852729A1 (de) *	1998-11-16	2000-05-18	Werner Reutter	Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
GB9825105D0 (en) *	1998-11-16	1999-01-13	Andaris Ltd	Pharamaceutical conjugates
EP1131415A4 (en) *	1998-11-18	2002-09-11	Neose Technologies Inc	PRODUCTION OF CHEAP OLIGOSACCHARIDES
AU764211C (en)	1998-12-01	2006-03-30	Abbvie Biotherapeutics Inc.	Humanized antibodies to gamma-interferon
CN1376164A (zh) *	1999-01-29	2002-10-23	霍夫曼-拉罗奇有限公司	Gcsf缀合物
US6365410B1 (en)	1999-05-19	2002-04-02	Genencor International, Inc.	Directed evolution of microorganisms
PE20010288A1 (es) *	1999-07-02	2001-03-07	Hoffmann La Roche	Derivados de eritropoyetina
AU6357900A (en) *	1999-07-20	2001-02-05	Amgen, Inc.	Hyaluronic acid-protein conjugates, pharmaceutical compositions and related methods
US6348558B1 (en)	1999-12-10	2002-02-19	Shearwater Corporation	Hydrolytically degradable polymers and hydrogels made therefrom
KR100729977B1 (ko)	1999-12-22	2007-06-20	넥타르 테라퓨틱스 에이엘, 코포레이션	폴리(에틸렌 글리콜)의 1-벤조트리아졸릴 카르보네이트에스테르의 제조 방법
AU2352201A (en)	1999-12-30	2001-07-16	Maxygen Aps	Improved lysosomal enzymes and lysosomal enzyme activators
CZ20022727A3 (cs) *	2000-01-10	2002-11-13	Maxygen Holdings Ltd	Polypeptidový konjugát, způsob jeho výroby a farmaceutický prostředek
US6423488B1 (en)	2000-01-15	2002-07-23	Avigenics, Inc	High throughput screening assay for detecting a DNA sequence
CN100488562C (zh) *	2000-02-11	2009-05-20	拜耳医药保健有限公司	凝血因子VⅡ或VⅡa样分子
AU2001232337A1 (en)	2000-02-18	2001-08-27	Kanagawa Academy Of Science And Technology	Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
KR100787073B1 (ko)	2000-06-28	2007-12-21	글리코파이, 인크.	변형된 당단백질의 제조방법
JP2004504016A (ja)	2000-06-30	2004-02-12	マキシゲン・エイピーエス	ペプチド拡張されたグリコシル化ポリペプチド
US20020064835A1 (en)	2000-07-10	2002-05-30	Diosynth Rtp, Inc.	Purification of human troponin I
WO2002013843A2 (en)	2000-08-17	2002-02-21	University Of British Columbia	Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
AU2001285020A1 (en)	2000-08-17	2002-02-25	Synapse Technologies, Inc.	P97-active agent conjugates and their methods of use
BR0207576A (pt)	2001-02-27	2004-04-27	Maxygen Aps	Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
CN105131104B (zh)	2001-10-10	2018-11-16	诺和诺德公司	肽的重构和糖缀合
JP3894776B2 (ja)	2001-11-09	2007-03-22	富士通メディアデバイス株式会社	吐出装置および吐出方法
WO2004000366A1 (en) *	2002-06-21	2003-12-31	Novo Nordisk Health Care Ag	Pegylated factor vii glycoforms
WO2004091499A2 (en) *	2003-04-09	2004-10-28	Neose Technologies, Inc.	Intracellular formation of peptide conjugates
JP4251399B2 (ja) *	2004-05-21	2009-04-08	独立行政法人産業技術総合研究所	Ｏ結合型糖鎖が付加されたペプチドのスクリーニング方法

2002
- 2002-10-09 CN CN201510483413.4A patent/CN105131104B/zh not_active Expired - Lifetime
- 2002-10-09 EP EP02795509A patent/EP1578771B1/en not_active Expired - Lifetime
- 2002-10-09 ES ES10012939.4T patent/ES2466024T3/es not_active Expired - Lifetime
- 2002-10-09 WO PCT/US2002/032263 patent/WO2003031464A2/en not_active Ceased
- 2002-10-09 EP EP09151346.5A patent/EP2080525B1/en not_active Expired - Lifetime
- 2002-10-09 BR BRPI0213207-9A patent/BRPI0213207B1/pt not_active IP Right Cessation
- 2002-10-09 AU AU2002360264A patent/AU2002360264B2/en not_active Expired
- 2002-10-09 MX MXPA04003333A patent/MXPA04003333A/es active IP Right Grant
- 2002-10-09 IL IL16125102A patent/IL161251A0/xx unknown
- 2002-10-09 PT PT100125368T patent/PT2279753E/pt unknown
- 2002-10-09 ES ES10012536.8T patent/ES2556338T3/es not_active Expired - Lifetime
- 2002-10-09 EP EP10012798.4A patent/EP2305314B1/en not_active Expired - Lifetime
- 2002-10-09 ES ES10012938.6T patent/ES2516041T3/es not_active Expired - Lifetime
- 2002-10-09 CN CN02820073XA patent/CN1635901B/zh not_active Expired - Lifetime
- 2002-10-09 EP EP10012797.6A patent/EP2305313B1/en not_active Expired - Lifetime
- 2002-10-09 HK HK06100136.9A patent/HK1080090B/zh not_active IP Right Cessation
- 2002-10-09 EP EP10184886.9A patent/EP2322229B1/en not_active Expired - Lifetime
- 2002-10-09 US US10/492,261 patent/US7416858B2/en not_active Expired - Lifetime
- 2002-10-09 JP JP2003534446A patent/JP5232352B2/ja not_active Expired - Lifetime
- 2002-10-09 EP EP10012794.3A patent/EP2305312B1/en not_active Expired - Lifetime
- 2002-10-09 CN CN200910145812.4A patent/CN101724075B/zh not_active Expired - Lifetime
- 2002-10-09 ES ES09000818.6T patent/ES2606840T3/es not_active Expired - Lifetime
- 2002-10-09 ES ES10012794.3T patent/ES2538342T3/es not_active Expired - Lifetime
- 2002-10-09 EP EP20100012793 patent/EP2305311A3/en not_active Withdrawn
- 2002-10-09 ES ES09151346.5T patent/ES2564688T3/es not_active Expired - Lifetime
- 2002-10-09 DK DK10012939.4T patent/DK2279755T3/da active
- 2002-10-09 EP EP09000818.6A patent/EP2042196B1/en not_active Expired - Lifetime
- 2002-10-09 ES ES02795509T patent/ES2411007T3/es not_active Expired - Lifetime
- 2002-10-09 EP EP10012795A patent/EP2292271A3/en not_active Withdrawn
- 2002-10-09 ES ES10184886T patent/ES2619371T3/es not_active Expired - Lifetime
- 2002-10-09 ES ES10012798T patent/ES2561985T3/es not_active Expired - Lifetime
- 2002-10-09 DK DK10184886.9T patent/DK2322229T3/da active
- 2002-10-09 EP EP10012938.6A patent/EP2279754B1/en not_active Expired - Lifetime
- 2002-10-09 ZA ZA200700168A patent/ZA200700168B/xx unknown
- 2002-10-09 CA CA2462930A patent/CA2462930C/en not_active Expired - Lifetime
- 2002-10-09 SG SG2006055305A patent/SG177002A1/en unknown
- 2002-10-09 PT PT100129394T patent/PT2279755E/pt unknown
- 2002-10-09 CN CN2011100354568A patent/CN102180944A/zh active Pending
- 2002-10-09 DK DK10012536.8T patent/DK2279753T3/da active
- 2002-10-09 SG SG200605529-7A patent/SG159381A1/en unknown
- 2002-10-09 EP EP10012796.8A patent/EP2298354B1/en not_active Expired - Lifetime
- 2002-10-09 EP EP10012536.8A patent/EP2279753B1/en not_active Expired - Lifetime
- 2002-10-09 DK DK02795509.5T patent/DK1578771T3/da active
- 2002-10-09 EP EP10185505A patent/EP2292273A3/en not_active Withdrawn
- 2002-10-09 NZ NZ532027A patent/NZ532027A/en not_active IP Right Cessation
- 2002-10-09 EP EP10012939.4A patent/EP2279755B1/en not_active Expired - Lifetime
- 2002-11-05 US US10/287,994 patent/US7138371B2/en active Active
2004
- 2004-04-01 IL IL161251A patent/IL161251A/en active IP Right Grant
- 2004-04-05 ZA ZA200402673A patent/ZA200402673B/en unknown
2006
- 2006-04-12 US US11/404,266 patent/US7276475B2/en not_active Expired - Lifetime
2008
- 2008-11-20 JP JP2008297209A patent/JP5376912B2/ja not_active Expired - Lifetime
2009
- 2009-06-16 AU AU2009202405A patent/AU2009202405B2/en not_active Expired
2010
- 2010-02-05 JP JP2010024516A patent/JP5258809B2/ja not_active Expired - Lifetime
- 2010-09-28 JP JP2010217733A patent/JP5739632B2/ja not_active Expired - Fee Related
- 2010-12-23 IL IL210257A patent/IL210257A/en not_active IP Right Cessation
2012
- 2012-05-07 JP JP2012106130A patent/JP2012143250A/ja active Pending
2014
- 2014-01-23 LU LU92359C patent/LU92359I2/fr unknown
- 2014-01-24 BE BE2014C004C patent/BE2014C004I2/fr unknown
- 2014-01-24 FR FR14C0007C patent/FR14C0007I2/fr active Active
- 2014-01-28 JP JP2014013799A patent/JP2014087370A/ja not_active Ceased
2015
- 2015-09-17 JP JP2015184218A patent/JP6316784B2/ja not_active Expired - Lifetime
2016
- 2016-06-14 JP JP2016118316A patent/JP6321724B2/ja not_active Expired - Lifetime
2017
- 2017-11-21 NL NL300912C patent/NL300912I2/nl unknown
- 2017-11-28 BE BE2017C059C patent/BE2017C059I2/nl unknown
- 2017-11-30 FR FR17C1053C patent/FR17C1053I2/fr active Active

Also Published As

Publication number	Publication date
DK1578771T3 (da)	2013-06-10
DK2322229T3 (da)	2017-03-27
EP2305313A3 (en)	2011-06-08
EP2298354A2 (en)	2011-03-23
BE2014C004I2 (da)	2021-11-22
EP2305314B1 (en)	2015-12-23
EP2279753B1 (en)	2015-09-16
HK1080090B (zh)	2012-12-14
JP2011006479A (ja)	2011-01-13
BRPI0213207B1 (pt)	2021-06-15
PT2279755E (pt)	2014-06-04
ES2466024T3 (es)	2014-06-09
CN101724075A (zh)	2010-06-09
EP2080525B1 (en)	2015-12-16
JP2016178938A (ja)	2016-10-13
AU2009202405B2 (en)	2011-09-22
ES2561985T3 (es)	2016-03-01
PT2279753E (pt)	2016-01-15
EP2322229B1 (en)	2016-12-21
JP2016037503A (ja)	2016-03-22
MXPA04003333A (es)	2006-02-22
EP2305312A3 (en)	2011-06-15
JP5232352B2 (ja)	2013-07-10
JP6321724B2 (ja)	2018-05-09
IL161251A0 (en)	2004-09-27
ES2564688T3 (es)	2016-03-28
JP2014087370A (ja)	2014-05-15
US7416858B2 (en)	2008-08-26
CN1635901B (zh)	2012-03-28
JP2005521635A (ja)	2005-07-21
HK1149513A1 (en)	2011-10-07
EP2279754A2 (en)	2011-02-02
FR17C1053I2 (fr)	2019-01-11
US7138371B2 (en)	2006-11-21
JP2009108087A (ja)	2009-05-21
EP2305312A2 (en)	2011-04-06
FR14C0007I1 (fr)	2014-02-28
IL210257A (en)	2015-07-30
CA2462930C (en)	2012-07-10
NL300912I2 (nl)	2018-09-27
SG177002A1 (en)	2012-01-30
EP2279753A2 (en)	2011-02-02
CN105131104B (zh)	2018-11-16
EP2305311A2 (en)	2011-04-06
EP2322229A2 (en)	2011-05-18
FR14C0007I2 (fr)	2015-01-02
EP2292271A2 (en)	2011-03-09
EP1578771A2 (en)	2005-09-28
IL161251A (en)	2013-07-31
DK2279755T3 (da)	2014-05-26
ES2556338T3 (es)	2016-01-15
CN1635901A (zh)	2005-07-06
HK1154498A1 (en)	2012-04-27
SG159381A1 (en)	2010-03-30
EP2322229A3 (en)	2012-03-07
ZA200700168B (en)	2010-02-24
FR17C1053I1 (da)	2018-01-12
NZ532027A (en)	2008-09-26
AU2002360264B2 (en)	2009-03-19
ES2411007T3 (es)	2013-07-04
CN102180944A (zh)	2011-09-14
JP5258809B2 (ja)	2013-08-07
ES2619371T3 (es)	2017-06-26
EP2080525A1 (en)	2009-07-22
US20040137557A1 (en)	2004-07-15
US20060287223A1 (en)	2006-12-21
EP2292273A3 (en)	2011-11-23
EP2279754A3 (en)	2011-06-22
EP1578771A4 (en)	2007-02-21
EP2292273A2 (en)	2011-03-09
ES2606840T3 (es)	2017-03-28
ES2516041T3 (es)	2014-10-30
JP5739632B2 (ja)	2015-06-24
IL210257A0 (en)	2011-03-31
ES2538342T3 (es)	2015-06-19
ZA200402673B (en)	2007-03-28
EP2279755A3 (en)	2011-06-15
HK1079797A1 (en)	2006-04-13
EP2305313B1 (en)	2014-03-26
JP2012143250A (ja)	2012-08-02
EP2298354A3 (en)	2011-06-08
EP2279753A3 (en)	2011-10-12
EP2279755A2 (en)	2011-02-02
US7276475B2 (en)	2007-10-02
EP2298354B1 (en)	2014-03-19
CN105131104A (zh)	2015-12-09
JP2010120954A (ja)	2010-06-03
EP2305311A3 (en)	2011-07-20
LU92359I2 (fr)	2014-03-24
EP2305314A3 (en)	2011-09-14
DK2279753T3 (da)	2015-11-23
EP1578771B1 (en)	2013-03-06
EP2292271A3 (en)	2011-09-14
EP2305314A2 (en)	2011-04-06
BR0213207A (pt)	2006-10-31
HK1080090A1 (en)	2006-04-21
EP2279754B1 (en)	2014-08-13
JP6316784B2 (ja)	2018-04-25
US20050106658A1 (en)	2005-05-19
EP2042196A2 (en)	2009-04-01
CA2462930A1 (en)	2003-04-17
JP5376912B2 (ja)	2013-12-25
EP2279755B1 (en)	2014-02-26
EP2042196B1 (en)	2016-07-13
EP2042196A3 (en)	2009-07-22
EP2305313A2 (en)	2011-04-06
EP2305312B1 (en)	2015-03-04
AU2009202405A1 (en)	2009-07-16
WO2003031464A2 (en)	2003-04-17
WO2003031464A3 (en)	2006-03-02
CN101724075B (zh)	2014-04-30

Publication	Publication Date	Title
BE2022C531I2 (da)	2022-08-09
BE2022C502I2 (da)	2023-04-12
FR17C1053I1 (da)	2018-01-12
BE2017C057I2 (da)	2022-02-01
BE2017C051I2 (da)	2021-11-22
BE2017C032I2 (da)	2021-07-19
BE2014C052I2 (da)	2022-02-01
BE2014C036I2 (da)	2021-11-22
BE2007C047I2 (da)	2021-06-04
AU2002307149A8 (da)	2002-10-21
BE2011C034I2 (da)	2021-11-22
JP2001223078A5 (da)	2008-03-13
BRPI0209186B1 (da)	2012-11-13
BE2017C050I2 (da)	2021-11-22
BRPI0204884B1 (da)	2011-05-17
CH1379220H1 (da)	2018-10-31
BE2016C021I2 (da)	2021-03-23
JP2002268142A5 (da)	2008-04-24
BRPI0101486B8 (da)	2021-05-25
BRPI0210463A2 (da)	2017-07-11
JP2002214501A5 (da)	2008-03-06
JP2002282476A5 (da)	2008-05-15
JP2002300389A5 (da)	2008-05-15
JP2002224317A5 (da)	2005-07-28
JP2001334931A5 (da)	2008-03-06